Recent developments of cathepsin inhibitors and their selectivity

Expert Opinion on Therapeutic Patents

Volumn 12, Issue 3, 2002, Pages 419-432

  Kim, Woomi ^a   Kang, Kooil ^a  

^a Kosin University   (South Korea)

Author keywords

Aspartic; Cathepsin inhibitor; Cysteine proteinase inhibitor; Proteinase inhibitor; Selectivity; Serine proteinase inhibitor

Indexed keywords

AMIDE; ASPARTIC PROTEINASE INHIBITOR; BENZAMIDOALDEHYDE DERIVATIVE; BUTYL AMIDE DERIVATIVE; CATHEPSIN; CATHEPSIN B; CATHEPSIN K; CATHEPSIN L; CATHEPSIN S; CEPHAM DERIVATIVE; CQ 002; CYSTEINE PROTEINASE INHIBITOR; DIACYL CARBOHYDRAZIDE DERIVATIVE; DIPEPTIDE DERIVATIVE; DIPEPTIDE NITRILE DERIVATIVE; EPOXYSUCCINAMIDE DERIVATIVE; FUROPYRROLIDINE DERIVATIVE; KETOAMIDE DERIVATIVE; KETOBENZAMIDE DERIVATIVE; MONOBACTAM DERIVATIVE; MORPHOLINOETHOXYBENZOFURAN DERIVATIVE; OXADIAZOLE DERIVATIVE; PENAM DERIVATIVE; PEPTIDE DERIVATIVE; PYROLOPYRROLIDINE DERIVATIVE; PYRROLIDINE DERIVATIVE; SERINE PROTEINASE INHIBITOR; SULFONAMIDE; THIADIAZOKE DERIVATIVE; THIAZOLE GUANIDINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; BRONCHITIS; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DRUG ACTIVITY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; EMPHYSEMA; HUMAN; HUNTINGTON CHOREA; IMMUNOMODULATION; METASTASIS; MUSCULAR DYSTROPHY; OSTEOPOROSIS; PATENT; REVIEW; RHEUMATOID ARTHRITIS; VIRUS INFECTION;

EID: 0036119488     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.12.3.419     Document Type: Review

References (41)

1. Cathepsin B in synovial cells at the site of joint destruction in rheumatoid arthritis
2. Pathogenesis of joint damage in rheumatoid arthritis
3. Cathepsin B and its endogenous inhibitor cystatin C in rheumatoid arthritis synovium
4. The cathepsin B inhibitor z-FA.fmk inhibits cytokine production in macrophages stimulated by lipopolysaccharide
5. Inhibition mechanism of cathepsin L-specific inhibitors based on the crystal structure of papain-CLIK148 complex
6. Localization of rat cathepsin K in osteoclasts and resorption pits: Inhibition of bone resorption and cathepsin K-activity by peptidyl vinyl sulfones
7. Inhibition of cathepsin K by nitric oxide donors: Evidence for formation of mixed disulfides and a sulfenic acid
8. Use of papain as a model for the structure-based design of cathepsin K inhibitors: Crystal structures of two papain-inhibitor complexes demonstrate binding to S′-subsites
9. Cathepsin D, urokinase plasminogen activator and type-1 plasminoben activator inhibitor in early breast cancer: An immunochemical study of prognostic value and relations to tenascin-C and other factors
10. Purification pepsins and cathepsin D by affinity chromatography on sepharose 4B with an immobilized synthetic inhibitor
11. New functional aspects od cathepsin D and cathepsin E
12. Urokinase-type plasminogen activator, plasminogen activator inhibitor Type 1 and cathepsin D: Analysis of their prognostic significance in squamous cell carcinoma of the head and neck
13. Cathepsins and their endogenous inhibitors in clinical oncology
14. The intracellular serpin proteinase inhibitor 6 is expressed in monocytes and granulocytes and is a potent inhibitor of the azurophilic granule protease, cathepsin G
15. Cathepsin A/protective protein: Anusual lysosomal multifunctional protein
16. Potency and selectivity of inhibition of cathepsin K, L and S by their respective properties
17. Cathepsin K and the design of inhibitors of cathepsin K
18. Structural basis for the biological specificity of cystatin C
19. The contribution of N-terminal region of cystatin A(Stefin A) to the affinity and kinetics of inhibition of papain, cathepsin B and cathepsin L
20. Cystatin inhibition of cathepsin B requires dislocation of the proteinase occluding loop. Demonstration by release of loop anchoring through mutation of his 110
21. Human cystatin C: Role of the N-terminal segment in the inhibition of human cysteine proteinases and in its inactivation by leukocyte elastase
22. Nuclear localization of cystatin B, the cathepsin inhibitor implicated in myoclonus epilepsy (EPM1)
23. Inhibitory properties of low molecular mass cysteine proteinase inhibitors from human sarcoma
24. Cathepsin B and its endogenous inhibitors: The role in tumour malignancy
25. Ras-responsive genes and tumour metastasis
26. The effect of an in vivo-injected thiol protease inhibitor, E-64-c, on the calcium-induced degeneration of myofilaments
27. Structure based development of novel specific inhibitors for cathepsin L and cathepsin S in vitro and in vivo
28. L-trans-epoxysuccinyl-leucylamido(4-guanidino)butane[E64] and its analogues as inhibitors of cysteine proteinases including cathepsin S, B, H and L
29. Novel epoxysuccinyl peptides: A selective inhibitor of cathepsin B, in vivo
30. Participation of cathepsin B in processing of antigen presentation to MHC class II
31. Tokaramide A, a new cathepsin B inhibitor from marine sponge Theonella aff. mirabilis
32. New-soluble formazan assay for HIV-1 cytopathic effects: Application to high-flux screening of synthetic and natural products for AIDS-antiviral activity
33. Kinetics of association of serine proteinases with native oxidized a1-proteinase inhibitor and a1-antichymotrypsin
34. Structure, function and control of neutrophil proteinases
35. The serpin superfamily of proteinase inhibitors: Structure, function and regulation
36. Multiple functions of neutrophil proteinases and their inhibitor complexes
37. DNA strongly impairsthe inhibition of cathepsin G by antichymotrypsin and proteinase inhibitor
38. Kinetic mechanism of the inhibition of cathepsin G by antichymotrypsin and proteinase inhibitor
39. Primary structure and properties of the cathepsin G/chymotrypsin inhibitor from the larval hemolymph of Apis mellifera
40. Serine proteinase inhibitor profiles in the hemolymph of a wide range of insect species
41. Enzymatic and molecular biochemical characterizations of human neutrophil elastases and a cathepsin G-like enzyme